Please check your internet connection and try again.
# Ecospirin (Aspirin) Enteric-Coated
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and antiplatelet properties. The enteric coating is designed to delay the release of aspirin until it reaches the small intestine, potentially reducing gastric irritation.
## Primary Indications
* **Pain and Inflammation:** Management of mild to moderate pain and inflammatory conditions (e.g., headache, muscle aches, arthritis).
* **Cardiovascular Prevention:** Prevention of thrombotic events (e.g., myocardial infarction, stroke) in patients with established cardiovascular disease or specific risk factors. This is often referred to as "low-dose" or "baby" aspirin therapy.
## Adult Dosing
* **Pain and Inflammation:**
* **Typical Dose:** 325 mg to 650 mg every 4 to 6 hours as needed.
* **Maximum Daily Dose:** Generally not to exceed 4000 mg per day, though lower maximums may be recommended for specific indications.
* **Cardiovascular Prevention (Antiplatelet):**
* **Typical Dose:** 75 mg to 325 mg once daily. The specific dose is often determined by local guidelines and individual patient risk assessment.
## Pediatric Dosing
* **Pain and Fever:**
* **Dose:** 10 mg/kg to 15 mg/kg per dose orally every 4 to 6 hours.
* **Maximum Daily Dose:** Not to exceed 75 mg/kg per day.
* **Kawasaki Disease:** Dosing is variable and typically guided by specialist recommendations, often starting at a higher dose for anti-inflammatory effects and then transitioning to a lower dose for antiplatelet effects.
* **Reye's Syndrome Warning:** Aspirin should generally be avoided in children and adolescents with viral illnesses due to the risk of Reye's syndrome.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Dose reduction may be necessary in severe renal impairment.
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary in severe hepatic impairment.
## Contraindications
* Hypersensitivity to aspirin, salicylates, NSAIDs, or any component of the formulation.
* Active peptic ulcer disease or history of gastrointestinal bleeding.
* Bleeding disorders (e.g., hemophilia, von Willebrand disease).
* Severe renal or hepatic impairment.
* Children and adolescents with viral infections (risk of Reye's syndrome).
* Third trimester of pregnancy.
## Adverse Effects
* **Common:** Gastrointestinal upset (indigestion, nausea, vomiting), heartburn.
* **Serious:** Gastrointestinal bleeding, ulceration, perforation, tinnitus, hearing loss, bronchospasm (especially in aspirin-sensitive asthmatics), nephrotoxicity, hepatotoxicity, Reye's syndrome (in children/adolescents with viral illness).
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 Inhibitors:** Increased risk of gastrointestinal toxicity and bleeding.
* **Corticosteroids:** Increased risk of gastrointestinal bleeding.
* **Methotrexate:** Increased risk of methotrexate toxicity.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, beta-blockers):** May reduce antihypertensive efficacy.
* **Uricosuric agents (e.g., probenecid):** May reduce uricosuric efficacy.
* **Valproic acid:** May increase valproic acid levels.
## Monitoring
* **For Pain/Inflammation:** Assess pain relief and signs of inflammation. Monitor for signs of gastrointestinal bleeding (melena, hematemesis) and tinnitus.
* **For Cardiovascular Prevention:** Monitor for efficacy in preventing thrombotic events and for signs of bleeding.
* **Renal and Hepatic Function:** Periodically monitor in patients with pre-existing impairment or those on long-term therapy.
## Clinical Pearls
* The enteric coating can delay absorption, which may affect the onset of action for pain relief compared to non-enteric coated formulations.
* Enteric coating does not eliminate the risk of gastrointestinal bleeding or ulceration, although it may reduce the frequency.
* For acute antiplatelet therapy (e.g., post-MI, stroke), non-enteric coated aspirin is often preferred for faster absorption.
* Concurrent use of proton pump inhibitors (PPIs) or H2 blockers may be considered in patients at high risk for gastrointestinal events, especially when using higher doses of aspirin.
* Always verify current prescribing information and local protocols for specific dosing recommendations, particularly for cardiovascular prevention and pediatric use.
***
**Disclaimer:** This information is intended for clinical use and does not replace the official prescribing information or professional medical advice. Always consult the most current drug monographs and patient-specific factors before making any treatment decisions.
